Effects of repeated doses of a fixed combination oral contraceptive containing 0.075 mg gestodene and 0.03 mg ethinylestradiol on the pharmacokinetics of roflumilast and roflumilast N-oxide

Study identifier:BY217/CP-038

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2006-004970-28

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

Female

Actual Enrollment

20

Study type

Interventional

Age

18 Years - 40 Years

Date

Study Start Date: 01 Feb 2007
Primary Completion Date: -
Study Completion Date: 01 Jan 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Sponsors

Takeda

Collaborators

-

Inclusion and exclusion criteria